Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Bipartisan Bill Before Congress Seeks to Force DEA to Allow Patient Use of Cannabis, Psychedelics

A bipartisan group of congressional lawmakers has filed a measure that would compel the U.S. Drug Enforcement Administration (DEA) to allow seriously ill patients to use psychedelics and cannabis. The bill would clarify that gravely ill individuals have the right to access alternative treatments under federal Right to Try (RTT) laws that allow them to use schedule 1 drugs if they don’t get any relief from traditional treatments.

An RTT policy signed into law by President Donald Trump when he was still in office already grants terminally ill patients access to investigational drugs that have gone through clinical trials, even if they are classified in schedule 1 of the Controlled Substances Act. However, the DEA refused to allow a Seattle physician to offer psilocybin therapy under RTT laws to patients with terminal conditions in 2021, forcing the doctor to file a series of lawsuits against the agency to compel it to grant psychedelic access to end-of-life patients.

The recent bill would amend existing law to clarify that despite the DEA’s move to reject psilocybin access under RTT laws, end-of-life patients should be able to use such treatments. The Right to Try Clarification Act was introduced by Representatives Nancy Mare and Earl Blumenauer and cosponsored by Representatives Andy Biggs, Lou Correa and Madeline Dean.

Led by Senators Rand Paul and Cory Booker and Representatives Early Blumenauer and Nancy Mae, a prior version of the bill was introduced in Congress last year, but it failed to advance.

Blumenauer said that patients with terminal illnesses have the right to discuss treatments such as psilocybin that could provide long-term relief from symptoms such as anxiety, depression and pain. He noted that such patients had been prevented from accessing beneficial treatments due to federal restrictions for too long and that the proposed bill would finally allow these individuals to try alternative treatments that could provide sustained relief regardless of the classification of the treatments on the Controlled Substances Act.

Forty-one states have Right to Try laws that allow terminally ill patients to access treatments in investigational stages, including psilocybin, Blumenauer said. He added that MDMA and psilocybin have exhibited much medical potential in early clinical trials. Despite this, Blumeauer continued, the DEA has “refused to accommodate” RTT laws and denied end-of-life patients the right to choose their preferred treatments.

If his bill succeeds, it could impact the ongoing case that has seen the DEA field lawsuits from a physician and patients trying to access psilocybin therapy.

Meanwhile, a number of companies, including IGC Pharma Inc. (NYSE American: IGC), are investing millions of dollars into developing therapeutic formulations from cannabis. These formulations could get approved by the FDA if the development process proceeds as the startups hope they will.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Montana Senators Reject Bill Seeking to Impose THC Limits, Ban Adult-Use Shops

Last Thursday, Montana’s Senate Committee for Economic and Labor Affairs approved SB 546 on a 6-to-4 vote count, giving it a pass for further Senate discussion. The bill, introduced by Senator Keith Regier, aimed to significantly reduce the potency of the medicinal cannabis plant and products in Montana by outlawing adult-use marijuana businesses, increasing the taxation on medical cannabis from 4% to 20%, and placing strict restrictions on the amount that can be legally possessed. It also aimed to reduce the number of marijuana plants grown for personal use from two to one.

Advocates for medicinal marijuana challenged the law, claiming it would prevent patients who depend on it for treating pain and other conditions from accessing it. Numerous individuals would not have been able to afford medical marijuana because of the anticipated tax rise.

Three GOP committee members — Committee Chair Jason Small, Senate President Jason Ellsworth and Senator Sales Walt — joined forces with all three Democratic members to reject the measure. Supporters of medical cannabis who have pushed for access to relatively affordable medical marijuana celebrated this ruling as a victory.

The strength of cannabis and youthful access were issues brought up by the bill’s supporters at the committee session on Thursday and the debate on Wednesday. Bill 546 would have reduced the permissible concentration of the psychoactive component THC in medicinal cannabis flowers from 35% to 10% and outlawed concentrates with higher THC concentrations.

The bill’s opponents said that it would have resulted in the loss of dozens of industrial jobs, encouraged the growth of a black market and prevented the state from collecting a significant amount of taxes. Although Small admitted that he favors some aspects of the proposal, he claimed that the bill is difficult to pass at this point of the session.

Currently, Montana regulation does not place a limit on the potency of cannabis extract products. The committee’s move to table the draft SB 546, which sought to regulate the strength of medical cannabis flower and extracts in Montana, suggests that additional discussion is required prior to passing any new laws.

It’s crucial to strike a balance between the demands of patients who require medical cannabis and worries about strength and young individuals’ access, as well as the effects on industry employment and tax income. The proposed measure might later be amended or reintroduced.

The failure of this measure leaves patients with marijuana cards still able to grow their own medicinal cannabis plants using some modern equipment, such as the mini-gardens sold by Advanced Container Technologies Inc. (OTC: ACTX).

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – IBN, CannabisNewsWire to Drive Reach of Lift Toronto 2023

IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands including CannabisNewsWire, today announced its latest event collaboration with the organizers of Lift Toronto, which will return to the iconic Metro Toronto Convention Centre in Toronto, Ontario, on June 1-3, 2023. Lift Toronto is projected to showcase 150-plus exhibiting companies, 140-plus speakers and featured panelists and draw up to 5,000 attendees to the event, which is open to all audiences across the full cannabis industry and community. IBN and CannabisNewsWire will leverage their array of extensive corporate communications solutions to drive recognition for Lift Toronto 2023 participants seeking to enhance visibility among investors, journalists, consumers and the broader public. “Lift is a highly professional organization with a long track record of successful cannabis events. We are very pleased to continue our collaboration as an official media sponsor and work with their wonderful team,” said Cami Cox, director of analytics and reporting for CannabisNewsWire. “Lift Toronto is the premier cannabis event in Canada and offers world-class educational opportunities for anyone in the space. Moreover, the diverse exhibitor list and high-powered networking make this event a favorite.”

To view the full press release, visit https://cnw.fm/pJ32d

About IBN

IBN (InvestorBrandNetwork) consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire (“IW”) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Germany to Proceed with Toned-Down Marijuana Legalization Plan as EU Review Awaits

Officials in Germany intend to move forward with a toned-down version of cannabis legalization after abandoning — at least temporarily — a more comprehensive proposal that would have brought about legal cannabis sales throughout the nation. Karl Lauterbach, the nation’s health minister, had promised to introduce new marijuana regulations by the end of March this year.

The new model, which consists of two parts, was first reported by Zeit and aims to legalize cannabis countrywide without breaking EU regulations. The model will, for four years, permit restricted cannabis sales in some areas, much like a pilot program. In doing so, officials would be able to observe how reforms were being implemented in both urban centers and more rural areas. The program can then be expanded to other regions of the nation if it is deemed successful.

Lauterbach’s plan would also permit Germans to cultivate marijuana for personal use. While the latter part of the plan would require review by the EU Commission, the former would not, according to reports.

Although specifics of the homegrow rules have not been decided, reports indicate that the proposal would permit consumers to own up to 30 marijuana plants. Additionally, independent cultivators can distribute the produce among themselves via “marijuana clubs.” These clubs are already legal in Spain and the Netherlands.

Last year, government representatives from the Netherlands, Germany, Luxembourg and Malta met to talk about legalizing marijuana. Moreover, the country’s federal cabinet approved a preliminary outline for a legalization bill at the end of last year, but the government wanted European Union approval to make sure that enacting the legislation wouldn’t violate international obligations.

Under that preliminary framework, persons older than 18 years of age would have legal access to possess up to 30 grams of cannabis, which could be bought from establishments with federal licenses. Eligible persons could also cultivate up to three marijuana plants for their own use, subject to restrictions on enclosure to keep minors out.

The plan calls for a special consumption tax in addition to the nation’s sales tax being applied to marijuana. And after the reform is put into effect, all ongoing criminal cases involving offenses that are now legal will be halted.

Earlier this month, Lauterbach stated that officials would be revising the proposal before introducing a bill in parliament as they had received “positive feedback” from the EU The framework was the result of several months of analysis and discussion between the German government and the nation’s coalition government. A series of hearings intended to inform legislation to end the nation’s prohibition were launched last summer by officials as a steppingstone toward legalization.

As more countries around the world take steps to end the prohibition of marijuana, many companies such as India Globalization Capital Inc. (NYSE American: IGC) are going a step further to develop medicines from compounds extracted from this plant, and these compounds are expected to gain the approval of regulators once the the clinical development process has been successfully completed.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Illinois Senate Approves Bill Blocking Police from Using Cannabis Smell as Probable Cause for Searches

Illinois Senators have voted in favor of a measure that would prevent law enforcement from using cannabis smell as a probable cause for vehicle searches. Senator Rachel Ventura sponsored the measure, which advanced in a 33-to-20 vote and is now headed to the Illinois House of Representatives for consideration.

Ventura said that her legislation was meant to protect Illinoisians from unreasonable searches at traffic stops. She noted that law enforcement tends to pull over people of color “far too often” and that the odor of cannabis shouldn’t be probable cause for these stops. Recreational cannabis is legal for both residents and nonresidents in the state, and the plant’s “pungent scent” sticks to clothing for long after initial consumption, she said.

While the measure would keep police officers from searching vehicles due to the cannabis smell, it will not make any changes to the state’s impaired driving policies, which ban driving while under the influence of cannabis.

According to a press release from Illinois Democrats, SB 125 was filed in response to a Will County case where a police officer pulled over and arrested a defendant after the officer detected “a strong odor of burnt cannabis” from the defendant’s vehicle. However, the defendant argued that they had smoked marijuana in the car “a long time ago.”

The response bill states that the odor of marijuana cannot be a probable cause to search vehicles, car operators, and passengers or individuals aged 21 years and older. The measure also eliminates a state law provision that required marijuana in cars be put in odor-proof vessels.

Illinois recreational cannabis is relatively new, launched in 2020, but it has proven lucrative already. The adult-use market generated more than $1.5 billion in sales and $446.4 million in taxes for the state government in 2022.

Still, Illinois officials acknowledge that the recreational cannabis market has a long way to go. A 2020 report from state cannabis regulators revealed that Illinois’ adult-use industry has a shocking lack of racial and gender diversity. At the time of the report’s release, there were no social-equity applicants, people with disabilities, and people of color with major ownership of licensed cannabis businesses and only one licensed business with majority female ownership.

White people comprised 88% of majority owners, 71% of minority owners, 90% of the board of directors and 80% of c-suite executives, while Latino and Black people made up less than 10% of senior positions. This move to address another vestige of the prohibition era is likely to be applauded by cannabis industry actors and other companies such as Advanced Container Technologies Inc. (OTC: ACTX) because needless arrests will decrease.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology

  • DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications
  • Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes
  • Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking IND status with the FDA

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a disruptive drug delivery technology with multiple opportunities for success in cannabinoids, oral nicotine and other active pharmaceutical ingredients (“APIs”). Lexaria’s patented DehydraTECH(TM) technology is a formulation and dehydration processing procedure that changes how the body detects and absorbs drugs. The company currently has 28 granted patents, with many more pending patents in countries worldwide.

Lexaria specifically designed DehydraTECH for formulating and delivering topical or oral lipophilic (fat-soluble) drugs and APIs to increase effectiveness and improve how they enter the bloodstream. The major benefits of a DehydraTECH-enabled drug or consumer product include the following:

  • Faster delivery time – the effects of the product are felt by the subject in minutes
  • Increased bioavailability – the technology is more effective at delivering a drug or product into the bloodstream
  • Increased brain absorption –testing suggests significant improvement in the quantity of the drug or product delivered across the blood-brain barrier
  • Improved drug potency – more of the drug or product is made available in the body, requiring lower dosages for the desired outcome
  • Reduced drug administration costs – lower dosages mean lower overall drug costs
  • Improved taste – the technology eliminates the necessity for sweeteners to eliminate or reduce unwanted taste

One of Lexaria’s studies is cannabidiol (“CBD”) for hypertension, which has produced positive results for the company to seek Investigational New Drug (“IND”) status with the United States Food and Drug Administration (“FDA”). The company has completed a pre-IND meeting and intends to file for IND status in 2023. Lexaria’s first and subsequent DehydraTECH-CBD human studies have shown superior human blood absorption levels and demonstrated a potential novel mechanism of action in reducing blood pressure. More information on Lexaria’s current studies can be found on the company’s fact sheet (https://ir.lexariabioscience.com/presentations).

The global non-prescription CBD market was valued at $4.9 billion in 2021 and is expected to reach $47.22 billion in 2028, growing at a CAGR of 21.3% (https://cnw.fm/Iqpis). There has also been increased product acceptance and use due to FDA approval of one type of CBD. CBD is being studied in a variety of medical applications worldwide, including anxiety and depression treatment, stress reduction, diabetes prevention, pain relief, cancer symptom relief, and inflammation relief. Lexaria is currently exploring DehydraTECH-CBD-enabled formulations for hypertension, epilepsy, diabetes and dementia indications.

Since 2016, Lexaria’s DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption, reduce onset time from hours to just minutes, and mask unwanted tastes. The company intends to further evaluate the technology for other oral and topical use potential in cannabinoids, oral nicotine and other APIs.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Colombian Legislators Work to Pass Cannabis Legalization Law This Year

Legislators in Colombia are looking to pass a bill that would legalize marijuana in the country this year. A Chamber of Representatives committee advanced the marijuana legalization bill in a 26-6 vote earlier this week.

The measure was reconciled from Senate and Chamber of Representatives versions in late 2022. Both Senate and Chamber of representatives versions of the bill sought to amend Colombia’s constitution to eliminate prohibitionist cannabis policies.

Lawmakers included language from the Chamber’s version of the measure that outlawed the possession and use of cannabis without a legal, medical prescription. The Chamber provisions limited marijuana marketing in public spaces and near school zones and placed a cap on marijuana consumption.

The language in the Chamber version stated that the bill would take 12 months to kick in after it was implemented. The Senate version of the bill was approved in a 56-3 vote in December 2022 after legislators convened for several weeks to discuss the legalization measure.

It included provisions that covered the autonomy of indigenous communities and acknowledged the communities’ right to regulate cannabis themselves.

Now that the bill has advanced past the First Committee of the Chamber, which represented its fifth stop in Congress, it will head to the floor for consideration before going to the Senate for a final vote. It has to go through a total of 8 stops in Congress over two years before heading to the president’s desk for final approval.

Justice Minister Nister Osuna said at the time that the country was the victim of an ‘absurd prohibitionist’ drug war that had ultimately failed while contributing to increased armed conflict, crime, and organized criminal activity.

In an op-ed, bill sponsor Rep Juan Carlos Losada said that the bill was one of the most controversial yet important issues in recent times.

Launching a regulated adult cannabis market would allow the country to abandon failed prohibitionist policies and provide an opportunity to create drug policies based on public health guidelines, efforts to prevent cannabis consumption, and increased attention to users.

He also noted that getting rid of prohibitionist policies would help the country reclaim the funds that have streamed into the illicit drug market and fueled violence and war in Colombia. Furthermore,  Rep Juan Carlos Losada said that a regulated market would do something that prohibition could not; save lives.

Colombia’s president Gustavo Petro has advocated for the end of international drug criminalization and recently urged UN member nations to adapt their drug policies and eliminate prohibitionist policies. These calls for drug policy reform at the international level are likely to grow louder over the coming years, as advocates keep an eye on how things shape up.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NBA to End Testing Players for Marijuana

Recent reports have indicated that the National Basketball Association (NBA) is striking cannabis from its list of banned drugs and ending marijuana testing for players. Athletic and Stadium reporter Shams Charania said that the NBA was removing cannabis testing as part of its new seven-year collective bargaining agreement and that the league had eliminated marijuana from its antidrug testing program.

The NBA’s stance on cannabis use among players has become more liberal in recent years. Last October, it was reported that the NBA would pause random cannabis drug tests for the third time in a row. Some insiders posited that the NBA would soon make the policy permanent, with journalist Ben Dowsett saying at the time that his sources had informed him the decision to halt cannabis screening would not be rescinded in the near future.

These speculations may have been right. In late 2020, NBA Commissioner Adam Silver indicated that the policy of scrapping cannabis tests would become permanent. This policy was initially implemented during the coronavirus pandemic when players were secluded in a quarantined bubble in Orlando to compete.

Silver said at the time that the league didn’t need to “act as Big Brother,” given the stress the players were under while competing in the quarantined bubble. Additionally, he said that society’s attitude toward cannabis had evolved and that the league would move away from mandatory blanket tests to talking to players who were exhibiting “signs of problematic dependency.”

Prior to the report of the potential ban, the National Basketball Players Association and the NBA had announced that they had worked out a “tentative agreement” on the new bargaining agreement but that the full details wouldn’t be publicized until they finalized a term sheet.

National Basketball Players Association (NBPA) Executive Director Tamika Tremaglio said in a public statement that the association’s goal is to protect players while enriching their lives both on and off the basketball court.

Cannabis use by professional athletes has been quite a sticky issue in recent months. The discussion became especially heated after American sprinter Sha’Carri Richardson was suspended from participating in the Tokyo Olympics due to a failed THC test.

Although the World Anti-Doping Agency (WADA) chose to keep cannabis on its banned substances list, America’s Major League Baseball (MLB) partnered with a CBD firm as its first marijuana sponsor. In 2021, the Ultimate Fighting Championship (UFC) also announced that it would stop punishing fighters who failed cannabis tests.

These changes within the sporting fraternity come amid changing attitudes at the general societal level, which have seen marijuana companies thrive alongside ancillary enterprises such as Advanced Container Technologies Inc. (OTC: ACTX) in states where the drug is legal.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Kentucky Governor Enacts Medical Cannabis Legalization Law

Only hours before the end of the 2023 session, a proposal to make medical marijuana legal in Kentucky went through the state senate on Thursday after ten years of fruitless attempts.

In front of a bipartisan group of lawmakers and supporters on Friday morning, Governor Andy Beshear enacted the legislation, putting Kentucky among the states resolving to end the prohibition of medicinal marijuana. The initiative will be active starting in early 2025.

In two of the previous three years, House Representatives had approved a medicinal marijuana measure, which was rejected at the Senate because of insufficient support from the party’s Republican caucus. The law was introduced on the floor of the Senate this year and was successfully passed through that chamber two weeks ago.

According to Senate Bill 47, the program as well as its growers, producers, and dispensaries would be subject to oversight, operation, implementation, and control by the Family Services and Health Cabinet.

In Kentucky’s approach, patients would qualify for a medical card for marijuana if they had one of at least six medical conditions; cancer of any kind, irrespective of the stage, crippling pain, seizure disorders, stiffness, persistent nausea, and PTSD are among the qualifying illnesses.

A patient may also qualify if they have a diagnosis of a sickness or health problem and the recently formed Cannabis Center decides that usage of cannabis would be beneficial. The center may decide that the individual is likely to obtain therapeutic, medical, or palliative benefits based on research and evidence.

Individuals getting medical marijuana from a dispensary will be able to ingest it through edible items and topical applications rather than smoking it.

Representative Jason Nemes, a proponent who previously served as the primary sponsor of medicinal cannabis legislation, cautioned the committee that, through the proposed bill, patients who choose to smoke cannabis rather than consume it in other ways would be in violation of the law and may potentially lose their medicinal marijuana cards.

Representative Matt Lockett, one of the bill’s critics, argued that since the law won’t be in practice until 2025, there is still time for it to be improved and passed the following year. Opposers of the bill claimed that there aren’t enough studies demonstrating the effectiveness and security of using cannabis as medical care.

Republican lawmakers celebrated the historic significance of the occasion at the signing function on Friday morning in Rotunda. They also celebrated the reality that thousands of people who are suffering will receive assistance.

While Kentucky is celebrating the enactment of a medical marijuana law, residents can also take additional comfort from the knowledge that there are companies like India Globalization Capital Inc. (NYSE American: IGC) that are working tirelessly to develop pharmaceutical-grade medicines from a number of cannabis compounds for the treatment of ailments like chronic pain.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – Delaware Senate Passes Cannabis Legalization Bills, Sends to Governor

Last Tuesday, the Senate in Delaware gave its nod of approval to a pair of proposals earlier voted through by the House that seek to legalize possession of cannabis and establish market regulations for the recreational consumption of cannabis. These bills will now be forwarded to the state’s governor.

The regulation proposal sailed through on a 15 to 5 vote tally, while the simple legalization proposal garnered a 16 to 4 tally in the chamber. Representative Ed Osienski sponsored both bills, which snaked their way through several legislative panels before getting a floor vote.

The sponsor made use of a similar, stratified approach for the legislation during the prior session, which resulted in the fundamental legalization draft being approved while the regulation version was narrowly defeated.

According to HB 1 as well as HB 2, the state laws would change to allow individuals over the age of 21 to have, share, use or buy as much as one ounce of marijuana. The measure stipulates that “independent person sharing” doesn’t entail distributing cannabis simultaneously with another reciprocating exchange involving the respective persons, such as exchanging a noncannabis item, to prevent abuse of the “gift-giving” provision. Marijuana cultivation as well as public use would remain illegal. Civil fines not exceeding $100 may be levied on under-aged individuals who engage in the banned behavior if it is their first violation. However, the police is at liberty to exercise restraint and impose a citation in lieu of a fine.

The measure offers a foundational framework for putting in place a controlled cannabis business system for recreational marijuana in the jurisdiction. Under the creation of the newly formed Office of the Commissioner for Marijuana Control, the Tobacco and Alcohol Enforcement Department (DATE) will be charged with overseeing the regulation of the market.

A maximum of 30 commercial cannabis permits may be issued by regulators after just 16 months of the market launching.

The scoring procedure before license issuance will give priority to candidates who demonstrate a capacity to offer a decent salary, health insurance, paid time off for illness and an emphasis on hiring a diverse pool of candidates.

A Fund for Justice Reinvestment that promotes transitional justice, job placement, technical support for the financially disadvantaged as well as similar initiatives would receive 7% of cannabis business fees.

Before this decision on Bill 2, members opposed two amendments proposed by the GOP. One intended to alter the Cannabis Regulation Commission’s organizational structure while also enabling those facing penalties, cancellation of licenses or license termination to request regulators to furnish them with the pertinent records backing such actions. This alternative bill could have removed any language referring to the necessity of marijuana companies to signing labor/employee peace agreements.

Marijuana legalization is sweeping across the country, and its growing popularity is aided by the R&D work being undertaken by enterprises such as India Globalization Capital Inc. (NYSE American: IGC), which hope to commercialize a number of medicinal formulations from different cannabinoids, such as THC.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.